These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 8972244)

  • 1. Chemoprophylaxis of diabetic nephropathy in the elderly.
    Jungmann E
    Drugs Aging; 1996 Dec; 9(6):449-57. PubMed ID: 8972244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention and treatment of diabetic nephropathy in older patients.
    Jungmann E
    Drugs Aging; 2003; 20(6):419-35. PubMed ID: 12710862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative effects of indapamide and captopril on blood pressure and albumin excretion rate in diabetic microalbuminuria.
    Donnelly R; Molyneaux LM; Willey KA; Yue DK
    Am J Cardiol; 1996 Feb; 77(6):26B-30B. PubMed ID: 8848991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal protection and antihypertensive drugs: current status.
    Salvetti A; Mattei P; Sudano I
    Drugs; 1999 May; 57(5):665-93. PubMed ID: 10353294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antihypertensive therapy in patients with diabetic nephropathy.
    Mehler PS; Schrier RW
    Kidney Blood Press Res; 1997; 20(2):74-81. PubMed ID: 9293422
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a study comparing two fixed-dose combination regimens to reduce albuminuria in patients with type II diabetes and hypertension.
    Bakris GL; Toto RD; McCullough PA
    J Hum Hypertens; 2005 Feb; 19(2):139-44. PubMed ID: 15457206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on urinary albumin excretion and renal function changes by delapril and manidipine in normotensive type 2 diabetic patients with microalbuminuria.
    Deerochanawong C; Kornthong P; Phongwiratchai S; Serirat S
    J Med Assoc Thai; 2001 Feb; 84(2):234-41. PubMed ID: 11336083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal protection in hypertensive patients: selection of antihypertensive therapy.
    Wenzel RR
    Drugs; 2005; 65 Suppl 2():29-39. PubMed ID: 16398060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).
    Dalla Vestra M; Pozza G; Mosca A; Grazioli V; Lapolla A; Fioretto P; Crepaldi G
    Diabetes Nutr Metab; 2004 Oct; 17(5):259-66. PubMed ID: 16295047
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure lowering for the prevention and treatment of diabetic kidney disease.
    Thomas MC; Atkins RC
    Drugs; 2006; 66(17):2213-34. PubMed ID: 17137404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal protection in diabetes--an emerging role for calcium antagonists.
    Parving HH; Tarnow L; Rossing P
    Cardiology; 1997; 88 Suppl 3():56-62. PubMed ID: 9397296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing end-stage renal disease.
    Mogensen CE
    Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and cost of antihypertensive treatment in incipient and overt diabetic nephropathy.
    Parving HH
    J Hypertens Suppl; 1998 Jan; 16(1):S99-101. PubMed ID: 9534107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].
    Bernadet-Monrozies P; Rostaing L; Kamar N; Durand D
    Presse Med; 2002 Nov; 31(36):1714-20. PubMed ID: 12467154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New antihypertensive therapy in diabetics].
    Passa P; Marre M; Leblanc H; Billault B
    Diabete Metab; 1987; 13(6):643-50. PubMed ID: 3329128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose angiotensin converting enzyme inhibitors: effect on renal function in normo- and hypertensive type 1 diabetic patients.
    Ciavarella A; Mustacchio A; Silletti A; Franchi R; Levorato M; Campieri C; Borgnino LC; Capozzi G; Morotti L; Vannini P
    Eur J Med; 1992 Sep; 1(5):268-72. PubMed ID: 1341608
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.